Company Overview / History
Company Overview
| Company Name | Immuno-Biological Laboratories Co., Ltd. |
|---|---|
| Foundation | September 9th, 1982 |
| President | Tsutomu Seito |
| Office Address |
Head Office Fujioka Laboratory 1091-1 Naka Aza-Higashida, Fujioka-Shi, Gunma 375-0005, JAPAN TEL: +81 (274) 22 2889 FAX: +81 (274) 23 6055 Mikasa Laboratory 440-22 Okayama, Mikasa-Shi, Hokkaido 068-2165, JAPAN TEL: +81 (1267) 2 3500 FAX: +81 (1267) 2 3443 Maebashi Laboratory 1-39-3 Asahi-cho , Maebashi-Shi, Gunma 371-0014, JAPAN TEL: +81 (27) 212 9700 FAX: +81 (27) 212 9701 |
| Capital | 50 million yen (As of 31st March 2025) |
| Employees | 58 (As of 31st March 2025) |
| Business Description |
■Research, develop, manufacture and supply various immunological research reagents, and customized services. ■Research and development on the materials used in diagnostic products and valuable seeds in our existing portfolio, and aim to obtain approval for their use in in-vitro diagnostic products and drugs. ■Research and development on state-of-the-art technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. |
| Main Banks |
■The Gunma Bank, Ltd. (Fujioka Branch) ■Mizuho Bank, Ltd. (Takasaki Branch) ■The Towa Bank, Ltd. (Fujioka Branch) |
History
| Sep. 1982 | IBL is established in Chiyoda Ward, Tokyo, with 5 million yen in capital, as a company that engages in the immunological study, development, production, and distribution of diagnostic reagents and research reagents. A laboratory is opened in Takasaki, Gunma, Japan. |
|---|---|
| Aug. 1986 | The laboratory is moved to Fujioka, Gunma, Japan. |
| Dec. 1987 | The head office is moved to Fujioka, Gunma, Japan. |
| Apr. 1994 | A factory is constructed in Fujioka Laboratory to boost production capacity. |
| Oct. 1999 | IBL successfully mass produces Arthritogenic mAb Cocktails, our first commissioned manufacturing. |
| Apr. 2001 | A new building with a transgenic research facility is constructed at the Fujioka Laboratory. |
| Mar. 2004 | IBL obtains ISO9001: 2000 certification. |
| Jun. 2004 | The head office is transferred to Takasaki. |
| Mar. 2005 | Mikasa Laboratory is opened with a laboratory animal breeding facility designed for drug seed discovery. |
| Mar. 2006 | IBL concludes a worldwide licensing agreement with Astellas Pharma Inc. The agreement grants Astellas the exclusive rights to develop, manufacture, and market IBL’s anti-human Osteopontin antibodies, including 2K1, for therapeutic use. |
| Mar. 2007 | IBL is listed on the Osaka Securities Exchange (Hercules Market). |
| Jan. 2009 | IBL obtains ISO13485 certification for the purpose of diagnostic agent quality control. (Antibody related Business) |
| May. 2010 | Acquire Neosilk Co., Ltd. |
| Jun. 2010 | The head office is moved to Fujioka-shi, Gunma, Japan. |
| Jan. 2012 | Enter a distribution agreement with Takara Bio Inc. for research reagent products. |
| Jul. 2013 | Acquire Skylight Biotech Inc. (Consolidated Subsidiary). |
| Nov. 2013 | Establish Neosilk Cosmetics Co., Ltd. (Consolidated Subsidiary). |
| Jul. 2016 | A pilot plant complied GMP for production of drug materials using transgenic silkworm technology is constructed in Maebashi City, Gunma prefecture. |
| Mar. 2019 | Acquired the shares of CURED Co., Ltd. by third-party allocation of shares and made it as an equity method affiliate. |
| Nov. 2021 | Absorption of the subsidiary, Skylight Biotech Inc. (Short form merger). |
